AdaptHealth (NASDAQ:AHCO) Trading Up 5.3% – Should You Buy?

AdaptHealth Corp. (NASDAQ:AHCO)’s stock price traded up 5.3% during mid-day trading on Tuesday . The company traded as high as $11.03 and last traded at $11.00. Approximately 105,022 shares traded hands during trading, a decline of 90% from the average daily volume of 1,064,513 shares. The stock had previously closed at $10.45.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AHCO. UBS Group lowered their price target on shares of AdaptHealth from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Canaccord Genuity Group decreased their price target on AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Robert W. Baird dropped their price objective on AdaptHealth from $16.00 to $14.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $13.00 price target on shares of AdaptHealth in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.17.

AdaptHealth Price Performance

The firm has a market cap of $1.43 billion, a PE ratio of -6.42, a PEG ratio of 1.48 and a beta of 1.11. The firm has a fifty day simple moving average of $10.67 and a two-hundred day simple moving average of $10.46. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24.

AdaptHealth (NASDAQ:AHCO) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.15 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.02). The business had revenue of $805.90 million for the quarter, compared to the consensus estimate of $809.32 million. AdaptHealth had a negative net margin of 6.57% and a positive return on equity of 9.62%. AdaptHealth’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter last year, the business earned $0.19 EPS. Equities analysts predict that AdaptHealth Corp. will post 0.89 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director David Solomon Williams III sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $11.26, for a total value of $45,040.00. Following the completion of the sale, the director now directly owns 36,899 shares of the company’s stock, valued at $415,482.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director David Solomon Williams III sold 4,000 shares of the firm’s stock in a transaction dated Thursday, August 29th. The shares were sold at an average price of $11.26, for a total value of $45,040.00. Following the completion of the sale, the director now owns 36,899 shares in the company, valued at approximately $415,482.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Shaw Rietkerk sold 25,000 shares of the stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $11.24, for a total transaction of $281,000.00. Following the completion of the sale, the chief operating officer now directly owns 212,611 shares in the company, valued at $2,389,747.64. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.43% of the stock is currently owned by insiders.

Hedge Funds Weigh In On AdaptHealth

Large investors have recently bought and sold shares of the business. Boston Partners purchased a new stake in shares of AdaptHealth during the first quarter valued at $693,000. Russell Investments Group Ltd. purchased a new stake in AdaptHealth in the 1st quarter valued at about $2,242,000. Hillsdale Investment Management Inc. bought a new position in AdaptHealth in the 1st quarter worth about $4,240,000. First Eagle Investment Management LLC increased its position in shares of AdaptHealth by 18.2% during the first quarter. First Eagle Investment Management LLC now owns 594,951 shares of the company’s stock worth $6,848,000 after acquiring an additional 91,772 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of AdaptHealth by 8.9% during the first quarter. Vanguard Group Inc. now owns 10,017,722 shares of the company’s stock valued at $115,304,000 after acquiring an additional 818,241 shares in the last quarter. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.